

Anti-BAFF & IL-17A Reference Antibody (Tibulizumab)

Catalog # APR11553

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9Y275 & Q16552
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information


Target/Specificity	TNFSF13B / BAFF / CD257,IL-17 / IL-17A / CTLA-8
Expression system	CHO

Protein Information

Images




Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 92.06%, determined by SEC-HPLC.


Tibulizumab bound to BAFF protein, and then rebounded to secondary antibodies (Anti-human- κ + λ -HRP), and read OD450. As shown in fig, Tibulizumab bound hu-BAFF-Fc, and the EC50 was 0.081 nM.



Tibulizumab bound to IL-17a protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Tibulizumab bound to in hu-IL-17a-His, and the EC50 was 0.128 nM.



Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Tibulizumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Tibulizumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 3.81 nM.



The detected molecular weight of Anti-BAFF & IL-17A Reference Antibody (Tibulizumab) is 201.34 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.